Point-of-care coagulation testing in patients suffering from COVID-19

• Conditions: U07.1; J80; COVID-19, virus identified; Adult respiratory distress syndrome

• Registration Number: DRKS00021255
• Lead Sponsor: Private Universität Witten/Herdecke gGmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patient suffering from COVID-19 in the need for critical care
Age > 17 years
Informed consent of either the patient or an independent physician and the relatives / legal caregiver

Exclusion Criteria

Age < 18 years
Refuse to participate
Not in the need for critical care

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation of the cumulative 7-day amplitude of the thrombelastometric measurements of native blood (NATEM) and the 30-day mortality. The maximum amplitudes (MCF, maximum clot firmness) of the daily thromlastometric measurements of the native blood (NATEM) are summed up. In the case of a homogeneous distribution, a correlation with the 30-day mortality is carried out. In the case of a multi-peak distribution, groups should be defined and their survival times analyzed.

Secondary Outcome Measures

Name	Time	Method
The correlation between cumulative blood coagulability in the first 7 days after admission to the intensive care unit and the ventilation-free days on the intensive care unit is the secondary outcome. See detailed procedure for the primary endpoint.